## CITATION REPORT List of articles citing

Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs

DOI: 10.1007/s00228-017-2289-0 European Journal of Clinical Pharmacology, 2017, 73, 1315-132

Source: https://exaly.com/paper-pdf/67613193/citation-report.pdf

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
14	Using the Symmetry Analysis Design to Screen for Adverse Effects of Non-vitamin K Antagonist Oral Anticoagulants. <i>Drug Safety</i> , <b>2018</b> , 41, 685-695	5.1	6
13	Patterns of direct oral anticoagulant drug prescription in France in 2010-2013: a study in the Midi-PyrBBs area. <i>European Journal of Clinical Pharmacology</i> , <b>2018</b> , 74, 945-951	2.8	4
12	Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 174-181	2.6	17
11	Underuse of Oral Anticoagulants in Patients With Ischemic Stroke and Atrial Fibrillation in China. <i>American Journal of Cardiology</i> , <b>2018</b> , 122, 2055-2061	3	9
10	Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation. <i>European Journal of Clinical Pharmacology</i> , <b>2018</b> , 74, 1653-1662	2.8	3
9	The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly. <i>International Journal of Cardiology</i> , <b>2018</b> , 265, 118-124	3.2	13
8	Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017. <i>Pharmacotherapy</i> , <b>2018</b> , 38, 907-920	5.8	107
7	Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study. <i>PLoS ONE</i> , <b>2019</b> , 14, e0221500	3.7	9
6	Venous thromboembolism 2011-2018 in Stockholm: a demographic study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 668-673	5.1	7
5	Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016. <i>BMJ Open</i> , <b>2019</b> , 9, e026645	3	33
4	Clinical characteristics and antithrombotic prescription in elderly hospitalized atrial fibrillation patients: A cross-sectional analysis of a Swedish single-center clinical cohort. <i>IJC Heart and Vasculature</i> , <b>2020</b> , 27, 100505	2.4	3
3	Temporal trends of atrial fibrillation and/or rheumatic heart disease-related ischemic stroke, and anticoagulant use in Chinese population: An 8-year study. <i>International Journal of Cardiology</i> , <b>2021</b> , 322, 258-264	3.2	4
2	AF-React study: atrial fibrillation management strategies in clinical practice-retrospective longitudinal study from real-world data in Northern Portugal. <i>BMJ Open</i> , <b>2021</b> , 11, e040404	3	
1	Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients. <i>European Heart Journal</i> , <b>2021</b> , 42, 3541-3	55 <sup>2</sup> 4 <sup>5</sup>	7